SEC Form 4 · accession 0000939767-17-000153
EXELIXIS, INC. · EXEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stelios Papadopoulos
Director
Period of report
Sep 18, 2017
Accepted (ET)
Sep 20, 2017 · 6:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000939767
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 18, 2017 | S | 72,210 | $27.76 | D | 1,162,104 | D | |
| Common StockF3 | Sep 19, 2017 | S | 127,790 | $27.63 | D | 1,034,314 | D | |
| Common StockF4 | holding | — | — | — | 10,000 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $27.74 to $27.78. Reporting Person undertakes to provide Exelixis, Inc., any security holder ofExelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to thisForm 4
- F2Includes 5,843 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
- F3Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $27.60 to $27.73. Reporting Person undertakes to provide Exelixis, Inc., any security holder ofExelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to thisForm 4
- F4Shares are held by Fondation Sante, of which the Reporting Person is co-trustee.